Verona Pharma Plc - Company Profile

Powered by

All the data and insights you need on Verona Pharma Plc in one report.

$ $295
Buy Report View Sample
  • Save hours of research time and resources with
    our up-to-date Verona Pharma Plc Strategy Report

  • Understand Verona Pharma Plc position in the market,
    performance and strategic initiatives.

  • Gain competitive edge and increase your
    chances of success

Back to companies

Verona Pharma Plc: Overview

Select Item

Related keylists

Verona Pharma Plc (Verona Pharma) is a clinical-stage biopharmaceutical company that focuses on the development and marketing of therapies for the treatment of respiratory diseases. The company’s lead investigating candidate, ensifentrine, a bronchodilator/anti-inflammatory agent intended for the treatment of chronic obstructive pulmonary disease (COPD) in Phase III clinical trials. Additionally the company is evaluating ensifentrine for the treatment of cystic fibrosis and asthma under its Phase II trials. Verona Pharma is headquartered in London, the UK.

 Gain a 360-degree view of Verona Pharma Plc and make more informed decisions for your business Gain a 360-degree view of Verona Pharma Plc and make more informed decisions for your business Find out more
Headquarters United Kingdom
Address Riverside, 3 More London Place, England, SE12RE
Website www.veronapharma.com
Telephone 44 20 32834200
No of Employees 79
Industry Pharmaceuticals and Healthcare
Ticker Symbol & Exchange VRNA (NASD)
EPS XYZ
Net Income (2022) XYZ 20.9% (2022 vs 2021)
Market Cap* $1.3B
Net Profit Margin (2021) XYZ -10,697.7% (2022 vs 2021)
   
* As of and is in US$
View Verona Pharma Plc financials
Gain access to our premium signals and make informed decisions for your business Gain access to our premium signals and make informed decisions for your business Find out more

Verona Pharma Plc premium industry data and analytics

30+

Catalyst Calendar

Proactively evaluate Verona Pharma Plc’s catalyst impacts to stay ahead of the competition & improve corporate planning. Bolster business development with timely opportunities.

30+

Clinical Trials

Determine Verona Pharma Plc go-to-market proposition and gain insight into the company’s clinical operations, recruitment, and trial strategy.

11+

Insights

Remove risk and uncertainty, gain a competitive edge and secure actionable leads with access to company-related investigative journalist content.

6

Pipeline Drugs

Identify which of Verona Pharma Plc’s products will be commercialized, helping you to better contend with shifting product portfolios, and allowing you to stay one step ahead of the market.

1

Regulatory Milestones

Track drug and patent expiries along with geographies impacted.

1

ICT Spend & Tech Priorities

IT Client Prospector provides intelligence on Verona Pharma Plc’s likely spend across technology areas enabling you to understand the digital strategy.

Products and Services

Products
Ensifentrine Pipeline:
Chronic Obstructive Pulmonary Disease (Nebulized & Inhaled)
Asthma (Nebulized & Inhaled)
XYZ
XYZ
XYZ
Understand Verona Pharma Plc portfolio and identify potential areas for collaboration Understand Verona Pharma Plc portfolio and identify potential areas for collaboration Find out more
Image for loader

Competitor Comparison

Key Parameters Verona Pharma Plc Novartis AG AstraZeneca Plc GSK plc Boehringer Ingelheim International GmbH
Headquarters United Kingdom Switzerland United Kingdom United Kingdom Germany
City London Basel Cambridge Brentford Ingelheim am Rhein
State/Province England - England England Rheinland-Pfalz
No. of Employees 79 76,057 89,900 70,212 53,000
Entity Type Public Public Public Public Private
Benchmark the company against the market with exclusive information on key competitors Benchmark the company against the market with exclusive information on key competitors Find out more
Chart Financial activity with access to more key stats Chart Financial activity with access to more key stats Find out more
Executives
Name Position Board Since Age
David Zaccardelli, Pharm. D. Chief Executive Officer; Director; President Executive Board 2020 58
Mark W. Hahn Chief Financial Officer Senior Management 2020 60
Kathleen Rickard, M.D. Chief Medical Officer Senior Management 2019 64
David Ebsworth, Ph.D. Chairman Non Executive Board 2014 68
Christopher Martin Senior Vice President - Commercial Senior Management 2020 -
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Non Dignissim Eros Proin vel Convallis 2024 XY
Gain insight into Verona Pharma Plc key executives to enhance your sales strategy Gain insight into Verona Pharma Plc key executives to enhance your sales strategy Find out more
Still looking?

Have you found what you were looking for? From start-ups to market leaders, uncover what they do and how they do it.

Explorer

Access more premium companies when you subscribe to Explorer

Get in touch about GlobalData Company reports

Contact the team or request a demo to find out how our data can drive your business forward